Empowered Funds LLC lessened its stake in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 11.1% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 21,532 shares of the biotechnology company's stock after selling 2,697 shares during the period. Empowered Funds LLC's holdings in United Therapeutics were worth $7,597,000 at the end of the most recent quarter.
Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Brooklyn Investment Group acquired a new position in shares of United Therapeutics in the third quarter valued at approximately $33,000. Capital Performance Advisors LLP purchased a new position in United Therapeutics in the 3rd quarter valued at approximately $82,000. MassMutual Private Wealth & Trust FSB grew its stake in shares of United Therapeutics by 31.9% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biotechnology company's stock worth $85,000 after acquiring an additional 58 shares in the last quarter. Values First Advisors Inc. purchased a new stake in shares of United Therapeutics during the third quarter worth $90,000. Finally, Emerald Mutual Fund Advisers Trust acquired a new stake in shares of United Therapeutics in the third quarter valued at $111,000. Hedge funds and other institutional investors own 94.08% of the company's stock.
Several research firms recently commented on UTHR. Argus boosted their target price on United Therapeutics from $360.00 to $400.00 and gave the stock a "buy" rating in a research note on Thursday, October 31st. UBS Group upped their target price on shares of United Therapeutics from $415.00 to $475.00 and gave the stock a "buy" rating in a research note on Wednesday, January 8th. The Goldman Sachs Group lifted their price target on shares of United Therapeutics from $243.00 to $302.00 and gave the stock a "neutral" rating in a research note on Friday, November 1st. LADENBURG THALM/SH SH increased their price objective on shares of United Therapeutics from $319.00 to $344.00 and gave the company a "buy" rating in a research report on Thursday, October 31st. Finally, StockNews.com upgraded shares of United Therapeutics from a "buy" rating to a "strong-buy" rating in a report on Thursday, January 16th. One analyst has rated the stock with a sell rating, two have given a hold rating, ten have given a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $382.08.
Check Out Our Latest Stock Analysis on UTHR
In other news, COO Michael Benkowitz sold 10,000 shares of the firm's stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $353.64, for a total transaction of $3,536,400.00. Following the transaction, the chief operating officer now directly owns 2,577 shares in the company, valued at approximately $911,330.28. This trade represents a 79.51 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Nilda Mesa sold 255 shares of the company's stock in a transaction on Monday, December 30th. The shares were sold at an average price of $355.77, for a total transaction of $90,721.35. Following the completion of the sale, the director now owns 5,528 shares of the company's stock, valued at approximately $1,966,696.56. This trade represents a 4.41 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 111,864 shares of company stock worth $41,036,365 in the last quarter. 11.90% of the stock is owned by insiders.
Shares of UTHR stock opened at $345.64 on Tuesday. United Therapeutics Co. has a 1 year low of $210.64 and a 1 year high of $417.82. The firm has a market cap of $15.43 billion, a price-to-earnings ratio of 15.18, a PEG ratio of 0.92 and a beta of 0.57. The stock's 50-day moving average is $362.37 and its two-hundred day moving average is $358.13.
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you make your next trade, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.
Our team has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and none of the big name stocks were on the list.
They believe these five stocks are the five best companies for investors to buy now...
See The Five Stocks Here
Before you consider United Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and United Therapeutics wasn't on the list.
While United Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.